Fig. 1

Design of Ad5-vectored SARS-CoV-2 variant vaccines. a Schematic organization of the SARS-CoV-2 S protein indicating the domains. The signal peptides were replaced with the tissue plasminogen activator, the furin cleavage site was deleted, and two proline substitutions at residues K986 and V987 were generated. The site mutations found in the S proteins of the B.1.1.7, P.1.351, P.1, B.1.429, B.1.617.1 and B.1.617.2 variants are noted in the S protein structure diagram (b, constructed using BIOVIA Discovery Studio Visualizer version 4.5 software) and listed in the table (c). d The transgene expression levels of Ad5-WT and Ad5-variant vaccines were validated through western blotting after infection in HEK293 cells